Drug intelligence / Profile preview

VLA2112

Development stage: Preclinical
Lead developer: Valneva
Modality: Vaccines & Immunotherapeutics
Administration: Unknown

Overview

VLA2112 is a vaccine candidate developed to target the Epstein-Barr virus (EBV), one of the most common human viruses. EBV is associated with infectious mononucleosis and has been implicated in several malignancies and autoimmune diseases. The mechanism of action for VLA2112 involves inhibition of EBV proteins, aiming to prevent infection or disease caused by this virus. The vaccine is being developed by Valneva SE and, as of the latest available information, remains in preclinical development[1][3].

Targets

EBNA1 (Epstein-Barr virus latency proteins)

Beyond the preview

Go deeper on VLA2112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VLA2112.

Explore the full profile